Department of Dermatology, Atatürk University Faculty of Medicine , Erzurum , Turkey.
J Dermatolog Treat. 2014 Jun;25(3):196-9. doi: 10.3109/09546634.2013.777381. Epub 2013 May 6.
The purpose of this study is to compare the efficacy of three therapies in the treatment of non-segmental vitiligo: a combination of topical calcipotriol, narrowband-ultraviolet B (NB-UVB), and betamethasone therapies; a combination of NB-UVB and topical calcipotriol; and NB-UVB alone.
Forty-five patients with non-segmental vitiligo presenting to our Dermatology clinic were recruited to participate in the study. Patients were randomly divided into three groups. For each patient the size of the depigmented areas was assessed according to the rule of nines. The first group was treated with a combination of topical calcipotriol, NB-UVB, and betamethasone therapies. The second group was treated with a combination of NB-UVB and topical calcipotriol and third group was treated with NB-UVB alone. Since the patients' vitiligo lesions had similar phototypes, all patients were started with 0.1 j/cm(2), regardless of their skin phototype. The dose of NB-UVB was increased 10% in each session and no further increment was done after reaching 2.5 j/cm(2). Treatment effectiveness was evaluated according to the percentage improvement in repigmentation. The quality of life of the patients was measured by the Dermatology Life Quality Index (DLQI).
The patients were aged from 13 to 55 years (mean: 25.29). The duration of disease ranged from 3 months to 20 years. Family history was positive for vitiligo in 10 patients (22.2%). The percentage of recovery after treatment was 63.33% ± 7.55 in group 1, 60.67% ± 5.75 in group 2, and 46.67% ± 7.98 in group 3. There was no statistically significant difference between groups 1 and 2, and groups 2 and 3, but there was a statistically significant difference between groups 1 and 3 (p = 0.0048).
In conclusion, NB-UVB-alone therapy and the combined therapies are effective treatment options in the treatment of vitiligo. Future studies with larger groups are warranted to confirm our results.
本研究旨在比较三种疗法治疗非节段性白癜风的疗效：钙泊三醇联合窄谱中波紫外线（NB-UVB）和倍他米松治疗；NB-UVB 联合钙泊三醇治疗；以及单独使用 NB-UVB 治疗。
招募了 45 名在皮肤科诊所就诊的非节段性白癜风患者参加本研究。患者被随机分为三组。根据九分法评估每位患者色素脱失区域的大小。第一组接受钙泊三醇、NB-UVB 和倍他米松联合治疗。第二组接受 NB-UVB 和钙泊三醇联合治疗，第三组单独接受 NB-UVB 治疗。由于患者的白癜风病变具有相似的光型，所有患者均从 0.1 j/cm²开始，无论其皮肤光型如何。每次治疗时将 NB-UVB 剂量增加 10%，达到 2.5 j/cm²后不再增加。根据色素再生的百分比评估治疗效果。通过皮肤病生活质量指数（DLQI）测量患者的生活质量。
患者年龄为 13 至 55 岁（平均年龄：25.29 岁）。疾病持续时间从 3 个月到 20 年不等。10 名患者（22.2%）有白癜风家族史。治疗后恢复的百分比分别为：第 1 组为 63.33%±7.55%，第 2 组为 60.67%±5.75%，第 3 组为 46.67%±7.98%。第 1 组和第 2 组、第 2 组和第 3 组之间无统计学差异，但第 1 组和第 3 组之间有统计学差异（p=0.0048）。
总之，NB-UVB 单独治疗和联合治疗是治疗白癜风的有效选择。需要进行更大规模的研究来证实我们的结果。
